[Hyderabad, April 17th, 2025] – The Aquaculture Vaccines Market, valued at 1.8 billion in 2023, will grow at 11.2% to 4.2 billion by 2031, as fish farms adopt advanced immunization, reports ClearView Market Insights.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-aquaculture-vaccines-market/
2024 Industry Milestones
- mRNA Breakthroughs
- Elanco's water-delivered mRNA vaccine prevents 95% of TiLV cases.
- RNAi-based shrimp vaccines enter commercial trials.
- Needle-Free Revolution
- PHARMAQ's oral vaccine survives digestive acids to trigger immunity.
- Yeast-vectored vaccines provide 3x longer protection.
- Climate Adaptation
- Thermostable vaccines withstand 30°C without refrigeration.
- Saline-tolerant formulations work across water types.
Regional Leaders
- Europe (40%): Norway vaccinates 100% of farmed salmon.
- Asia-Pacific (XX%): Vietnam's shrimp vaccine mandate.
- Americas (XX%): Chile's USD 1B+ vaccinated salmon industry.
Executive Insights
"We're vaccinating fish more precisely than humans now – with mRNA and oral tech."
– Jeff Simmons, CEO, Elanco
Roadmap to 2031
- 2025: 50% of shrimp farms transition from antibiotics to vaccines.
- 2027: mRNA vaccines cover 30% of salmon production.
- 2030: Universal fish vaccines targeting multiple pathogens expected.
For more insights, visit https://clearviewmarketinsights.com/report-store
About ClearView Market Insights
ClearView Market Insights analyzes more than 80 animal health markets, spanning from livestock to aquaculture.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
